Received: 15 February 2021
Accepted: 16 December 2021
First Online: 4 January 2022
: Comprehensive consent was obtained from accusable patients in our institution.Besides comprehensive consent, specific informed consent for this study was not required because this was a retrospective study with an opt-out option. The protocol of this study was approved and informed consent was waived by the institutional review board (committee member: Kohei Omatsu. Gynecologic Oncology Department) of the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan (approved number: # 2020–1280).This study had conducted in accordance with ethical guidelines for medical and health research involving human subjects.
: No personal information is included.Not applicable.
: The authors have competing interests in relation to this study.Competing interests are listed below.Y. Ozaki reports personal fees from Chugai.T. Takano reports grants and personal fees from Daiichi-Sankyo, Kyowa Kirin, Eisai, and Chugai; grants from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Merck Serono, Taiho, and Novartis; and personal fees from Pfizer, Eli Lilly, and Celltrion.F. Hara reports grants, personal fees from Chugai, Pfzer, Kyowa Kirin, Eli Lilly Japan.T. Ueno received personal fees from Chugai, AstraZeneca, Taiho, and Novartis and grants and personal fees from Eisai.No COI of other co-authors.